Home List your patent My account Help Support us

New Asthma, COPD and Breathing Disorders Drug Discovery!

[Category : - Food- HEALTH]
[Viewed 2973 times]

Dear Drug Discovery and Healthcare Investors,

I would like to introduce to you my Natural Drug Discovery for Respiratory and Lung Diseases (Asthma, COPD, Bronchitis etc.). I believe my product has great potential and a huge market. I would like to explore the possibility of cooperation with you and your company. I am enclosing my presentation and would appreciate your response!

SOLIAIR™ Product Overview:

SOLIAIR™ is a blend of botanical extracts and a food supplement that contains a unique composition of ingredients, which has reported beneficial impact. SOLIAIR™ can contribute to strengthening the respiratory system and may help patients in chronic respiratory diseases such as Obstructive Lung Disease, Asthma, Bronchitis, COPD (Chronic Obstructive Pulmonary Disease) and other respiratory infections.

Each SOLIAIR™ food supplement has been authorized and defined by the Israeli Ministry of Health and according to Pharmacists Regulation. The SOLIAIR™ has a patent pending!

SOLIAIR™ Adventage:

The Situation Today of Conventional Drug Therapy:

1. Has limited efficacy in patients with asthma and can not significantly inhibit the deterioration of respiratory function in patients with COPD and does not reduce disease exacerbations, hospitalization and mortality.
2. Causes side effects.
3. Is expensive.

Patients taking SOLIAIR™ reported a decrease in seasonal infections of the respiratory tract. Reducing the incidence of respiratory infections benefit tremendous potential. The SOLIAIR™ food supplement is free of side effects and has no interaction with conventional medication used for treatment of respiratory disorders!

- Please Contact the SOLIAIR™ Team for Full Patent/IP Details!

* SOLIAIR™ Company Presentation & Overview (PowerPoint + Video): goo.gl/6faUeJ

Financial information

SOLIAIR™ - Consumer/Market Problem and Size:

COPD and Asthma are Common Diseases: 5% of Americans over the age of 18 and 5-10% of Israelis are suffering or will suffer from COPD. It is estimated that 340 million people worldwide suffer from this disease. Estimates show that in Israel 2% of adults suffer from asthma. In the U.S. incidence of the disease in adults is close to 8%.

Therapy costs for COPD and its complications totaled in 2006 at $176.8 billion and are expected to rise to $389.2 billion by 2011 and to $832.9 billion by 2021!

Respiratory Infections are an important factor in worsening the clinical course of chronic lung disease and increase the mortality of these diseases. Respiratory infections, including seasonal flu also damage the healthy young population and has serious economic damage bearings due to absenteeism from work and school and a cause for hospital admissions.

The SOLIAIR™ Team Is Looking for a Person or a Company that:

- 1. Will commercialize the product.
- 2. Handle all the certification to sell the product.
- 3. Export the product worldwide.
- Or an outright sale / a license with royalties.

* SOLIAIR™ Company Presentation & Overview (PowerPoint + Video): goo.gl/6faUeJ

- Please Contact the SOLIAIR™ Team for Full Patent/IP Details!

Best Regards,
SOLIAIR™ Team

Patent publications:

No publication

Asking price:

1,000,000 USD

Rate this patent

Great invention
Liked: 1 times

Viewed: 2973 times

Seller:

soliair (Israel)

Seller's website

Ask a question
or start a negotiation

Contact the seller

Share on social media